CJC-1295 Half-Life in the Research Literature

The measured timeline

The published CJC-1295 half life data is variant-specific, and the distinction is the whole point. For the long-acting DAC form, the estimated half-life is 5.8 to 8.1 days in healthy adults, measured in the study that established the compound's human kinetics ^[1]. For the no-DAC form, Modified GRF (1-29), the half-life is short — minutes to hours — reflecting native GHRH(1-29) clearance with the four substitutions slowing enzymatic degradation but no albumin tether to extend plasma residence ^[1].

That multi-day figure for the DAC variant is the number the entire long-acting design exists to produce, and it is why the DAC form is dosed far less frequently than the short-acting form. The albumin conjugation is the mechanism; the 5.8-to-8.1-day half-life is the measured result. Every kinetic claim on this page is variant-tagged, because an untagged CJC-1295 half-life figure is meaningless when the two forms differ by orders of magnitude.

Why the DAC form lasts so long

The duration traces to the albumin bioconjugation. The maleimidopropionyl handle on the DAC variant bonds covalently to serum albumin, and albumin is a long-lived plasma protein. By tethering the peptide to it, the conjugate inherits a plasma residence approaching albumin's own, which is what pushes the half-life into days ^[2].

The rat data made this concrete before the human study: the albumin-conjugated peptide was detectable in plasma beyond 72 hours and produced a 4-fold increase in growth-hormone area-under-the-curve over two hours versus the unconjugated peptide ^[2]. The four substitutions alone confer protease resistance; the albumin conjugation is what confers the multi-day duration. Remove the conjugation, as in the no-DAC form, and the long half-life disappears ^[1].

IGF-1 outlasts the dose

The downstream IGF-1 response extends past the growth-hormone response. In healthy adults, IGF-1 rose 1.5- to 3-fold and stayed elevated for nine to eleven days after a single dose; after multiple doses, IGF-1 remained above baseline up to 28 days ^[1]. The hormone the analog ultimately raises lingers in circulation well beyond the immediate growth-hormone pulse.

That 28-day IGF-1 elevation after repeat dosing is a key part of the kinetic picture and a key part of the safety conversation, because sustained IGF-1 elevation is the basis for the theoretical concerns covered on the FAQ. The reported and theoretical side effects of CJC-1295 are read against exactly this prolonged-elevation profile.

The no-DAC form clears on a different scale entirely

The short-acting no-DAC form, Modified GRF (1-29), occupies the opposite end of the kinetic range. Without the albumin handle, it has no mechanism to extend plasma residence, so its clearance tracks native GHRH(1-29) — minutes to hours — with the four substitutions doing nothing more than slowing enzymatic breakdown ^[1]. There is no multi-day tail, no 28-day IGF-1 elevation, and no albumin reservoir slowly releasing peptide back into circulation.

This is why the variant designation is not a footnote on a half-life page; it is the whole question. A claim of a multi-day half-life belongs only to the DAC conjugate. The same molecule stripped of its DAC handle has a half-life in a different order of magnitude ^[2]. Any kinetic figure quoted without naming the variant is unreadable, and the DAC vs no-DAC pharmacokinetics page exists to keep the two apart.

The practical signature of the two profiles is frequency. A compound with a 5.8-to-8.1-day half-life accumulates and persists across days from a single administration; a compound cleared in hours does not. The duration is the differentiator, and it is the differentiator the marketing most often erases.

What the half-life does not tell you

A long half-life describes how long the compound and its downstream hormone persist; it does not describe efficacy, safety, or appropriate use. The pharmacokinetic studies that produced the 5.8-to-8.1-day figure were early-phase human PK work, not efficacy or long-term safety trials ^[1]. The kinetics are characterized; the clinical outcomes are not.

The original long-acting DAC program was discontinued. A ConjuChem Phase 2 trial in HIV-associated visceral obesity was halted, and the DAC program did not advance to approval ^[1]. CJC-1295 is not approved for human use anywhere, and its multi-day kinetics are a property of the molecule, not a clearance from any regulator.

The kinetics also carry a safety dimension that the duration figures make plain. A 28-day IGF-1 elevation after repeat dosing means exposure is not a brief event, and sustained IGF-1 elevation is precisely the profile behind the epidemiologic cancer-risk concern ^[11]. A long half-life is a pharmacological feature, not a reassurance — it means the system stays activated for longer, for better or worse. This page documents the timeline; it does not recommend acting on it.